A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Amcasertib (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Boston Biomedical
- 22 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.